Literature DB >> 19528963

Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia.

B Rodríguez-Santiago1, A Brunet, B Sobrino, C Serra-Juhé, R Flores, Ll Armengol, E Vilella, E Gabau, M Guitart, R Guillamat, L Martorell, J Valero, A Gutiérrez-Zotes, A Labad, A Carracedo, X Estivill, L A Pérez-Jurado.   

Abstract

Copy number variants (CNVs) are a substantial source of human genetic diversity, influencing the variable susceptibility to multifactorial disorders. Schizophrenia is a complex illness thought to be caused by a number of genetic and environmental effects, few of which have been clearly defined. Recent reports have found several low prevalent CNVs associated with the disease. We have used a multiplex ligation-dependent probe amplification-based (MLPA) method to target 140 previously reported and putatively relevant gene-containing CNV regions in 654 schizophrenic patients and 604 controls for association studies. Most genotyped CNVs (95%) showed very low (<1%) population frequency. A few novel rare variants were only present in patients suggesting a possible pathogenic involvement, including 1.39 Mb overlapping duplications at 22q11.23 found in two unrelated patients, and duplications of the somatostatin receptor 5 gene (SSTR5) at 16p13.3 in three unrelated patients. Furthermore, among the few relatively common CNVs observed in patients and controls, the combined analysis of gene copy number genotypes at two glutathione S-transferase (GST) genes, GSTM1 (glutathione S-transferase mu 1) (1p13.3) and GSTT2 (glutathione S-transferase theta 2) (22q11.23), showed a statistically significant association of non-null genotypes at both loci with an additive effect for increased vulnerability to schizophrenia (odds ratio of 1.92; P=0.0008). Our data provide complementary evidences for low prevalent, but highly penetrant chromosomal variants associated with schizophrenia, as well as for common CNVs that may act as susceptibility factors by disturbing glutathione metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528963     DOI: 10.1038/mp.2009.53

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  36 in total

Review 1.  Genetic association studies of antioxidant pathway genes and schizophrenia.

Authors:  Kodavali V Chowdari; Mikhil N Bamne; Vishwajit L Nimgaonkar
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

Review 2.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients.

Authors:  A Monin; P S Baumann; A Griffa; L Xin; R Mekle; M Fournier; C Butticaz; M Klaey; J H Cabungcal; P Steullet; C Ferrari; M Cuenod; R Gruetter; J P Thiran; P Hagmann; P Conus; K Q Do
Journal:  Mol Psychiatry       Date:  2014-08-26       Impact factor: 15.992

4.  Oxidative/Nitrosative stress in psychiatric disorders: are we there yet?

Authors:  Patricio O'Donnell; Kim Q Do; Celso Arango
Journal:  Schizophr Bull       Date:  2014-04-08       Impact factor: 9.306

5.  Blood-based gene-expression biomarkers of post-traumatic stress disorder among deployed marines: A pilot study.

Authors:  Daniel S Tylee; Sharon D Chandler; Caroline M Nievergelt; Xiaohua Liu; Joel Pazol; Christopher H Woelk; James B Lohr; William S Kremen; Dewleen G Baker; Stephen J Glatt; Ming T Tsuang
Journal:  Psychoneuroendocrinology       Date:  2014-09-30       Impact factor: 4.905

6.  Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients.

Authors:  Jacobine E Buizer-Voskamp; Jan-Willem Muntjewerff; Eric Strengman; Chiara Sabatti; Hreinn Stefansson; Jacob A S Vorstman; Roel A Ophoff
Journal:  Biol Psychiatry       Date:  2011-04-13       Impact factor: 13.382

7.  Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome.

Authors:  Anne S Bassett; Chelsea Lowther; Daniele Merico; Gregory Costain; Eva W C Chow; Therese van Amelsvoort; Donna McDonald-McGinn; Raquel E Gur; Ann Swillen; Marianne Van den Bree; Kieran Murphy; Doron Gothelf; Carrie E Bearden; Stephan Eliez; Wendy Kates; Nicole Philip; Vandana Sashi; Linda Campbell; Jacob Vorstman; Joseph Cubells; Gabriela M Repetto; Tony Simon; Erik Boot; Tracy Heung; Rens Evers; Claudia Vingerhoets; Esther van Duin; Elaine Zackai; Elfi Vergaelen; Koen Devriendt; Joris R Vermeesch; Michael Owen; Clodagh Murphy; Elena Michaelovosky; Leila Kushan; Maude Schneider; Wanda Fremont; Tiffany Busa; Stephen Hooper; Kathryn McCabe; Sasja Duijff; Karin Isaev; Giovanna Pellecchia; John Wei; Matthew J Gazzellone; Stephen W Scherer; Beverly S Emanuel; Tingwei Guo; Bernice E Morrow; Christian R Marshall
Journal:  Am J Psychiatry       Date:  2017-07-28       Impact factor: 18.112

8.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

9.  Impaired Cerebellar Development in Mice Overexpressing VGF.

Authors:  Takahiro Mizoguchi; Masamitsu Shimazawa; Kazuki Ohuchi; Yoshiki Kuse; Shinsuke Nakamura; Hideaki Hara
Journal:  Neurochem Res       Date:  2018-11-20       Impact factor: 3.996

Review 10.  NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?

Authors:  Joseph C Masdeu; Josep Dalmau; Karen F Berman
Journal:  Trends Neurosci       Date:  2016-04-26       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.